Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gross Profit: 2021-2024

Historic Gross Profit for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to $26.2 million.

  • Amylyx Pharmaceuticals' Gross Profit fell 77.63% to $26.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $110.4 million, marking a year-over-year decrease of 72.82%. This contributed to the annual value of $108.3 million for FY2024, which is 73.32% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Gross Profit stood at $26.2 million for Q4 2024, which was up 6,205.05% from $416,000 recorded in Q3 2024.
  • Amylyx Pharmaceuticals' Gross Profit's 5-year high stood at $117.3 million during Q4 2023, with a 5-year trough of $285,000 in Q3 2021.
  • Moreover, its 3-year median value for Gross Profit was $52.7 million (2023), whereas its average is $54.0 million.
  • Its Gross Profit has fluctuated over the past 5 years, first skyrocketed by 28,338.93% in 2023, then slumped by 99.61% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Gross Profit (Quarterly) stood at $285,000 in 2021, then surged by 31.58% to $23.7 million in 2022, then spiked by 393.98% to $117.3 million in 2023, then slumped by 77.63% to $26.2 million in 2024.
  • Its last three reported values are $26.2 million in Q4 2024, $416,000 for Q3 2024, and $1.0 million during Q2 2024.